Wealthfront Advisers LLC Buys Shares of 10,596 DaVita Inc. $DVA
Wealthfront Advisers LLC has acquired 10,596 shares of DaVita Inc. (NYSE:DVA) for approximately $2.357 million during the second quarter. This move comes as several other institutional investors have also adjusted their stakes in the company. DaVita recently reported strong earnings, beating analyst estimates, and has received mixed but generally positive analyst ratings, with an average target price of $221.75.
Mitsubishi UFJ Asset Management Co. Ltd. Takes Position in DaVita Inc. $DVA
Mitsubishi UFJ Asset Management Co. Ltd. has acquired a new position in DaVita Inc. (NYSE:DVA), purchasing 39,712 shares valued at approximately $8.8 million, giving them a 0.06% stake in the company. Institutional investors collectively own 90.12% of DaVita, which recently reported strong quarterly earnings exceeding expectations with $4.02 EPS and $3.55 billion in revenue. Despite a mixed analyst sentiment leading to a "Hold" rating, the company issued optimistic fiscal 2026 EPS guidance.
Danske Bank A S Invests $13.11 Million in DaVita Inc. $DVA
Danske Bank A S has acquired a new stake of 58,943 shares in DaVita Inc. (NYSE:DVA) totaling approximately $13.11 million during the second quarter. Other institutional investors have also adjusted their positions in DVA, while insiders have made transactions, and analysts have set new price targets. DaVita reported strong Q2 earnings, exceeding analyst expectations, and provided its FY 2026 guidance.
DaVita dialysis clinic in Novi has repeated deficiencies as families demand answers after 2 deaths
Families are demanding answers and stricter regulations after two patients died following treatment at a DaVita dialysis clinic in Novi, Michigan, in June. A review of a decade of inspection records reveals repeated deficiencies at the facility, including issues with sanitation, maintenance, and infection control, despite which the clinic was rated in compliance overall and allowed to reopen quickly. The families, along with a nephrologist, are raising concerns about the repeated nature of these problems and calling for stronger oversight.
DaVita stock steadies after Q2 revenue growth but EPS outlook disappoints
DaVita Inc. (DVA) saw its stock stabilize after reporting solid Q2 2026 revenue growth of 5.2% to $3.55 billion, surpassing analyst expectations. However, the company's weaker full-year EPS outlook led to an initial post-earnings pullback, though shares remain significantly up year-to-date. Investors are weighing the strong top-line performance against concerns about profitability and margin pressures.
Patients Share Their Experiences With Expanded HD
DaVita is expanding access to Expanded hemodialysis (HD), and some patients have reported positive personal experiences, including improved daily well-being. This treatment utilizes a specialized dialyzer like Nipro’s ELISIO-HX to effectively remove larger, complex toxins (middle molecules) that standard high-flux hemodialysis struggles with, thereby addressing issues like chronic inflammation, cardiovascular challenges, and daily symptom burden. While individual patient stories are encouraging, ongoing research continues to evaluate the broader clinical impact of Expanded HD.
DaVita Inc. stock underperforms Thursday when compared to competitors
DaVita Inc. (DVA) stock fell 1.15% to $175.24 on Thursday, underperforming the broader market. This marked the second consecutive day of losses for the company, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines.
DaVita stock slips after Q2 revenue beats forecasts
DaVita Inc. (US23918K1088) reported strong Q2 2026 results, with revenue of $3.55 billion and adjusted EPS of $4.02, exceeding analyst expectations. Despite these positive financial figures and a 5.2% year-over-year revenue increase, the stock experienced a 1.87% decline. Analysts maintain a "Hold" rating with a consensus price target significantly above the current trading price, indicating continued support despite the post-earnings slip.
Outpatient & Specialty Care Stocks Q2 Teardown: U.S. Physical Therapy (NYSE:USPH) Vs The Rest
This article analyzes the Q2 earnings of U.S. Physical Therapy (NYSE:USPH) and several of its peers in the outpatient and specialty care industry. It highlights that while the sector saw strong Q2 results with revenues beating estimates, share prices have generally declined. The article details individual company performances, noting LifeStance Health Group (NASDAQ:LFST) as a top performer and DaVita (NYSE:DVA) as the weakest against analyst estimates.
DaVita (NYSE: DVA) director now holds 5,970 shares after award
DaVita Inc. director Adam H. Schechter was granted 278 shares of Common Stock as an award on August 15, 2026. This transaction increased his direct holdings to 5,970 shares. The shares were recorded at a price of $0.00 per share, indicating a compensation-related stock award rather than an open-market purchase.
DaVita (NYSE: DVA) reports new insider stock trade
DaVita Inc. (NYSE: DVA) has reported an insider stock transaction involving Director Barbara J. Desoer. According to a Form 4 SEC filing, Desoer acquired 278 shares of common stock, bringing her direct holdings to 278 shares and indirect holdings to 14,021 shares through a trust. The filing indicates the transaction's sentiment and impact as neutral.
DaVita (NYSE: DVA) director Phyllis Yale gets 278-share stock award
DaVita Inc. director Phyllis R. Yale received an award of 278 shares of common stock on August 15, 2026, classified as a grant/award acquisition with a reported price of $0.00 per share. Following this transaction, Yale directly holds 9,803 shares of DaVita common stock. This insider activity was disclosed in a Form 4 filing, indicating no sales or derivative transactions.
DaVita (NYSE: DVA) insider logs new stock trade in SEC filing
A recent SEC Form 4 filing indicates that DaVita (NYSE: DVA) director Arway Pamela M acquired 278 shares of common stock on August 15, 2026, as a grant/award. This transaction resulted in Arway Pamela M directly owning 27,223 shares of common stock after the acquisition. The filing was accepted by the SEC on August 18, 2026, and is assessed as having a neutral impact and sentiment.
Forever Committed to Excellence in Care: DaVita Community Care Report 2025
DaVita has released its 2025 Community Care Report, highlighting over 25 years of leadership in patient-centered kidney care, including consistent high ratings under CMS's Five-Star Quality system. The report details DaVita's initiatives in value-based care through DaVita IKC, expanded home dialysis options, and efforts to improve kidney transplant access and education, while serving a diverse patient population and providing free Kidney Smart education.
DaVita Inc. stock underperforms Monday when compared to competitors
Shares of DaVita Inc. (DVA) fell 1.87% on Monday, closing at $176.70. This underperformance occurred during a negative trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average experiencing declines. The stock is currently 28.60% below its 52-week high of $247.49, which was reached on August 3rd.
DaVita Inc. (DVA) Stock Analysis: A Strong ROE And 21% Potential Upside
DaVita Inc. (DVA), a leading provider of kidney dialysis services, showcases a strong return on equity (ROE) of 88.48% and over $1 billion in free cash flow, making it an attractive prospect in the healthcare sector. Analysts project a potential upside of 21.31% with a target price range of $165.00 to $270.00, averaging $218.43. While technical indicators suggest recent downward momentum, the company's strategic growth initiatives and impressive financial efficiency position it for continued relevance and growth.
Enterprise value to revenue forward of DaVita Inc. – BX:TRL
This article displays the "Enterprise value to revenue forward" metric for DaVita Inc. (BX:TRL). It indicates that the value for this specific financial metric is "No trades" and is made by humans. The article is primarily a data point display from TradingView, offering financial information on the company.
Stronger Q2 Earnings and Transplant Focus Might Change The Case For Investing In DaVita (DVA)
DaVita Inc. reported stronger Q2 2026 earnings with increased revenue and net income, supporting its margin-focused strategy despite ongoing risks like lower treatment volumes and reimbursement pressures. The company also emphasized its role in strengthening kidney transplant ecosystems. While efficiency efforts are boosting earnings, investors should consider DaVita's projected growth to $15.7 billion revenue and $1.1 billion earnings by 2029, which suggests a fair value of $208.57 per share.
Bank of America Corp DE Cuts Holdings in DaVita Inc. $DVA
Bank of America Corp DE reduced its stake in DaVita Inc. by 33.4% in the first quarter, selling 120,642 shares but still retaining 241,059 shares valued at approximately $37.0 million. Despite this reduction, other institutional investors increased their holdings, leading to institutional ownership of 90.12% of the stock. DaVita exceeded Q1 earnings expectations, reporting $4.02 EPS against a $3.88 consensus, and maintaining its fiscal 2026 EPS guidance.
LifeStance Health Surpasses Q2 Earnings Expectations Driven by Clinician Growth
LifeStance Health significantly exceeded Q2 earnings expectations, reporting $435.4 million in revenue and an adjusted EPS of $0.11, driven by a 26.1% year-over-year growth and improved operational efficiency. The company raised its full-year guidance for both revenue and EBITDA, reflecting strong management confidence. This success is largely attributed to its expanding clinician base, now over 8,500, and the effective adoption of digital workflow tools in the rapidly growing mental health market.
How Cigna’s Dividend Hike And Jefferies’ Downgrade At Cigna Group (CI) Has Changed Its Investment Story
Cigna Group recently announced a US$1.56 per share cash dividend, while Jefferies downgraded its rating to "hold" due to anticipated 2027 earnings headwinds. This creates a mixed investment outlook, balancing Cigna's commitment to returning capital with concerns about future earnings sustainability amid regulatory scrutiny and affordability pressures. The company's fair value is estimated at $340.92, suggesting a 23% upside, though analyst opinions on its valuation vary widely.
Rockwell Medical Q2 2026 slides: narrowing losses, targeting profitability
Rockwell Medical reported narrowing losses and increased revenue in Q2 2026, driven by new customers and operational efficiencies, despite narrowly missing analyst expectations. The company is progressing towards its goal of positive adjusted EBITDA for the full year 2026 and aims for significant growth and profitability by 2029 through strategic initiatives and portfolio diversification. Rockwell operates in a growing hemodialysis market, serving major providers and hospitals, and plans to expand its product offerings and global presence.
DaVita Inc. stock outperforms competitors despite losses on the day
Despite a daily loss of 1.28% for its stock, DaVita Inc. (DVA) outperformed the broader market, which saw the S&P 500 and Dow Jones Industrial Average rise. DaVita's shares closed at $179.17, still significantly below its 52-week high achieved earlier in August.
Encompass Health Corporation (EHC) Stock forecasts
This article provides stock forecast information for Encompass Health Corporation (EHC), noting that Argus has raised its target price for EHC to $138.00. The company's current price is $123.78, and it operates in the healthcare sector, providing post-acute healthcare services.
DaVita Inc. (DVA) Stock forecasts
Argus has lowered its target price for DaVita Inc. (DVA) to $187.00. DaVita is identified as the largest provider of dialysis services in the United States, holding approximately 35% market share by clinics. The current price of DVA stock is $181.41.
DaVita Inc. stock outperforms competitors on strong trading day
DaVita Inc. (DVA) saw its stock advance by 1.77% to $181.50 on Wednesday, outperforming the mixed market session. This rise ended a two-day losing streak for the company's shares. The S&P 500 Index rose 0.26%, while the Dow Jones Industrial Average fell 0.04%.
DaVita Community Care Report 2025: Creating a Culture of Belonging for All
DaVita released its 2025 Community Care Report, emphasizing its commitment to fostering a culture of belonging for all teammates. The report highlights internal programs like the "Basics of Belonging" course, the "Week of Belonging," and Teammate Resource Groups, which have contributed to an 85% teammate engagement score in 2025. DaVita also details its Redwoods campus recruiting program, focused on developing diverse leadership, and its strong EEO-1 benchmark performance in representation.
DaVita Inc. $DVA Shares Sold by Wedge Capital Management L L P NC
Wedge Capital Management L L P NC reduced its stake in DaVita Inc. by 22.8% in the second quarter, selling 55,101 shares and retaining 186,227 shares valued at $41.4 million. Despite institutional investors owning over 90% of the company, analyst sentiment is mixed, with some upgrading to "buy" and others lowering price targets, resulting in a consensus "hold" rating with an average target of $221.75. DaVita surpassed quarterly expectations, reporting $4.02 EPS on $3.55 billion in revenue, a 5.2% year-over-year increase.
Are Wall Street Analysts Bullish on DaVita Stock?
DaVita Inc. (DVA) shares have significantly outperformed the broader market and the healthcare sector over the past year, despite a dip after its Q2 2026 results due to weaker revenue per treatment. Analysts expect DaVita's adjusted EPS to grow by 35.2% in fiscal year 2026, with a "Moderate Buy" consensus rating and a mean price target suggesting a nearly 27% upside. Concerns remain regarding the impact of ACA subsidy losses on treatment volumes and revenue.
DaVita Inc. $DVA Shares Sold by Empowered Funds LLC
Empowered Funds LLC significantly reduced its stake in DaVita Inc. by 85.7% in the first quarter, selling 19,673 shares and retaining 3,293 shares. Despite this sell-off, other institutional investors like Arrowstreet Capital and Norges Bank increased their holdings, with institutional investors collectively owning 90.12% of DaVita. DaVita exceeded Q1 earnings and revenue expectations, reporting $4.02 EPS and $3.55 billion in revenue, yet analysts maintain a "Hold" rating with a target price of $221.75.
SURE Dividend: 0.69% Yield, $1.29/Share — History & Dates
This article provides a comprehensive overview of the AdvisorShares Insider Advantage ETF (SURE) dividend, including its current yield of 0.69% ($1.29 per share annually) and a payout ratio of 0.28. It details the ETF's dividend history since 2011, ex-dividend dates, and growth rates, showing a 5-year dividend growth rate of 13.57%. The article also addresses frequently asked questions about SURE's dividend and provides historical data charts.
DaVita Inc. stock underperforms Tuesday when compared to competitors
DaVita Inc. (DVA) stock declined by 2.91% on Tuesday, closing at $178.34, underperforming the broader market. This marked the stock's second consecutive day of losses, as the S&P 500 Index and Dow Jones Industrial Average also experienced slight declines.
DaVita Inc. $DVA Shares Acquired by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. increased its stake in DaVita Inc. (NYSE:DVA) by 30.5% in the second quarter, acquiring 10,477 additional shares, bringing its total holdings to 44,783 shares valued at approximately $9.96 million. DaVita reported strong quarterly earnings of $4.02 per share, surpassing analyst expectations, and revenue grew 5.2% year-over-year to $3.55 billion. The company has an average "Hold" rating from analysts with a consensus price target of $221.75, despite mixed individual analyst recommendations.
DaVita Inc. (DVA) Stock Analysis: Strong Upside Potential with an 18.86% Gain on the Horizon
DaVita Inc. (NYSE: DVA) is presented as a compelling investment opportunity in the healthcare sector, specifically in kidney dialysis services, with a market capitalization of $11.8 billion. Analysts project an 18.86% upside potential from its current trading price of $183.77, with an average target price of $218.43. Despite mixed analyst sentiment, the company demonstrates strong financial health with high return on equity and significant free cash flow, suggesting long-term growth driven by rising demand for kidney care.
9,300 Shares in DaVita Inc. $DVA Purchased by Polianta Ltd
Polianta Ltd. recently acquired 9,300 shares of DaVita Inc. (NYSE:DVA) valued at approximately $2.07 million, making DVA the 20th largest holding in Polianta's portfolio. Institutional investors collectively own over 90% of DaVita stock. The company's recent earnings beat analyst estimates, with EPS of $4.02 and revenue up 5.2% year over year, though analyst sentiment remains mixed with an average "Hold" rating.
ProShares S&P 500 Buyback Aristocrats ETF's DaVita Inc(DVA) Holding History
This article details the historical holdings of DaVita Inc (DVA) by the ProShares S&P 500 Buyback Aristocrats ETF. As of May 31, 2026, the ETF held 897 shares of DVA, valued at $174,340, representing 1.88% of its portfolio. The ETF has an estimated gain of 9.77% on its DVA holdings since its initial trade in Q2 2026.
DaVita Inc. (DVA) Stock Forecasts
Morningstar analyst Julie Utterback reports on DaVita Inc. (DVA), a major dialysis service provider, stating that the company's shares fell after management maintained its 2026 outlook. The report highlights DaVita's significant market share in the U.S. dialysis sector and its large patient base, primarily served by government payers. The article also provides related analyst reports from other firms with their target price adjustments.
DaVita Inc. (DVA) Stock Forecasts
DaVita Inc. (DVA) saw its stock fall after management maintained its 2026 outlook. Morningstar's senior analyst, Julie Utterback, covers the company, which is a leading provider of dialysis services in the U.S. with a significant market share. The report highlights DaVita's market position and analyst ratings, including a current price of $183.77.
DaVita Inc. stock outperforms competitors on strong trading day
DaVita Inc. (DVA) stock increased by 1.72% on Friday, closing at $183.77, snapping a four-day losing streak. This performance outpaced the broader market, with the S&P 500 Index rising 0.62% and the Dow Jones Industrial Average rising 0.28% on the same trading day.
DaVita Shares Rise After TD Cowen Upgrades Stock to Buy
DaVita shares rose after TD Cowen upgraded the stock from Hold to Buy and increased its price target to $220. This upgrade was based on DaVita's strengthening competitive position, improving long-term growth prospects, and the potential impact of the MOTheR trial. The upgrade follows better-than-expected quarterly results and a recent share price pullback which TD Cowen views as an attractive buying opportunity.
Truist Adjusts Price Target on DaVita to $215 From $250, Maintains Hold Rating
Truist has lowered its price target for DaVita (NYSE: DVA) to $215 from $250, while reiterating a "Hold" rating on the stock. This adjustment comes amidst other analyst actions on DaVita, with some firms raising and others adjusting their price targets, and follows DaVita's recent Q2 2026 earnings report.
Janus Henderson Group PLC Raises Stock Position in DaVita Inc. $DVA
Janus Henderson Group PLC significantly increased its stake in DaVita Inc. by 96.2% during the first quarter, acquiring an additional 18,237 shares to total 37,188 shares valued at approximately $5.7 million. Other institutional investors also adjusted their positions, with institutional ownership now standing at 90.12%. DaVita recently reported strong quarterly earnings, beating estimates with $4.02 EPS on $3.55 billion revenue, and maintained its 2026 adjusted EPS guidance despite some concerns about narrowing margins and reimbursement pressures.
Why is DaVita stock up 2% today?
DaVita HealthCare Partners Inc. stock rose 2.1% in pre-open trading today after TD Cowen upgraded the kidney dialysis provider from Hold to Buy, increasing its price target to $220 from $201. Analysts cited an improving market position, new care modality potential from MOTheR trial results, and the stock's discounted entry point after Q2 2026 results which beat consensus but led to a sharp sell-off due to flat full-year guidance.
Why is DaVita stock up 2% today?
DaVita HealthCare Partners Inc. (DVA) stock rose 2.1% after TD Cowen upgraded the kidney dialysis provider from Hold to Buy, increasing its price target to $220 from $201. This upgrade follows a post-earnings sell-off despite beating Q2 2026 estimates, creating a discounted entry point that TD Cowen highlighted. The firm cited an improving market position and new care modalities as key drivers for future growth.
Can DaVita’s (DVA) Better Mortality Trends Redefine Its Core Dialysis Investment Story?
DaVita Inc. (DVA) reported strong Q2 2026 results with increased revenue and net income, alongside improved patient mortality and treatment volumes. The company's core dialysis business shows promise, with management reaffirming its 2026 outlook and deploying advanced hemodialysis dialyzers. Despite these clinical gains and growth, investors are cautioned about potential ongoing margin pressures from reimbursement and rising input costs.
DaVita Inc. $DVA Shares Bought by California State Teachers Retirement System
The California State Teachers Retirement System increased its stake in DaVita Inc. (NYSE:DVA) by 21.6% in the first quarter, acquiring an additional 8,046 shares to own a total of 45,243 shares valued at approximately $6.95 million. Institutional investors and hedge funds now collectively own 90.12% of DaVita's stock. Despite DaVita exceeding second-quarter expectations with adjusted EPS of $4.02 and revenue of $3.55 billion, analysts remain cautious with a consensus "Hold" rating, as management reaffirmed rather than raised full-year guidance, and lower revenue per treatment and higher expenses pressured margins.
Akebia Therapeutics Q2 Earnings Call Highlights
Akebia Therapeutics (NASDAQ: AKBA) reported its Q2 2026 earnings, highlighting a significant 60% year-over-year increase in Vafseo revenue to $21.3 million, driven by over 10,500 active patients. The company also announced that its VOICE trial for Vafseo met its interim stopping criteria, demonstrating a statistically significant reduction in mortality and hospitalization. Despite these successes, total revenue declined to $49.1 million due to generic competition impacting Auryxia sales, and the company anticipates a potential decline in Vafseo revenue in 2027 due to pricing reductions after its TDAPA period ends.
DaVita Stock Down in Pre-Market Despite Q2 Earnings Beat, Margins Down
DaVita (DVA) reported adjusted earnings of $4.02 per share in Q2 2026, surpassing the Zacks Consensus Estimate, with revenues of $3.55 billion also exceeding expectations. Despite beating earnings and revenue forecasts and seeing an increase in U.S. dialysis treatments, the company's stock fell in pre-market trading due to a decline in gross and operating margins. DaVita also revised its 2026 outlook, maintaining adjusted EPS guidance but expecting treatment volume near the top end of its previous range.
What To Expect From LifeStance Health Group’s (LFST) Q2 Earnings
LifeStance Health Group (LFST) is set to announce its Q2 earnings this Thursday. The company exceeded revenue expectations last quarter, reporting $403.5 million, and analysts anticipate a 20.1% year-on-year revenue growth for the upcoming quarter. Despite past revenue misses, peer performance suggests a mixed outlook, with LFST's stock currently down 6.7% over the last month.
DaVita Inc. stock underperforms Wednesday when compared to competitors
Shares of DaVita Inc. (DVA) plunged 17.24% on Wednesday, closing at $188.69. This underperformance occurred during a mixed trading session where the Dow Jones Industrial Average rose, but the S&P 500 Index fell. The stock experienced its third consecutive day of losses.
